METTL3 and pancreatic adenocarcinoma: As shown in Figure 2A–E, higher expression levels of METTL3 were significantly associated with poorer overall survival in ACC, KICH, and LIHC, whereas they were significantly associated with better overall survival in MESO, and PAAD.